Published in:
Open Access
01-12-2017 | Original Communication
Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study
Authors:
Sara Mariotto, Sergio Ferrari, Salvatore Monaco, Maria Donata Benedetti, Kathrin Schanda, Daniela Alberti, Alessia Farinazzo, Ruggero Capra, Chiara Mancinelli, Nicola De Rossi, Roberto Bombardi, Luigi Zuliani, Marco Zoccarato, Raffaella Tanel, Adriana Bonora, Marco Turatti, Massimiliano Calabrese, Alberto Polo, Antonino Pavone, Luisa Grazian, GianPietro Sechi, Elia Sechi, Daniele Urso, Rachele Delogu, Francesco Janes, Luciano Deotto, Morena Cadaldini, Maria Rachele Bianchi, Gaetano Cantalupo, Markus Reindl, Alberto Gajofatto
Published in:
Journal of Neurology
|
Issue 12/2017
Login to get access
Abstract
Anti-myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) recently emerged as a potential biomarker in patients with inflammatory demyelinating diseases of the central nervous system. We here compare the clinical and laboratory findings observed in a cohort of MOG-Ab seropositive and seronegative cases and describe IgG subclass analysis results. Consecutive serum samples referred to Verona University Neuropathology Laboratory for aquaporin-4 (AQP4)-Ab and/or MOG-Ab testing were analysed between March 2014 and May 2017. The presence of AQP4-Ab was determined using a cell-based assay. A live cell immunofluorescence assay was used for the detection of MOG-IgG and IgG subclass analysis. Among 454 analysed samples, 29 were excluded due to AQP4-Ab positivity or to the final demonstration of a disorder not compatible with MOG-Ab. We obtained clinical data in 154 out of 425 cases. Of these, 22 subjects resulted MOG-Ab positive. MOG-Ab positive patients were mainly characterised by the involvement of the optic nerve and/or spinal cord. Half of the cases presented relapses and the recovery was usually partial. Brain MRI was heterogeneous while short lesions were the prevalent observation on spinal cord MRI. MOG-Ab titre usually decreased in non-relapsing cases. In all MOG-IgG positive cases, we observed IgG1 antibodies, which were predominant in most subjects. IgG2 (5/22), IgG3 (9/22) and IgG4 (3/22) antibodies were also detectable. We confirm that MOG-Ab-related syndromes have distinct features in the spectrum of demyelinating conditions, and we describe the possible role of the different IgG subclasses in this condition.